- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03460977
PF-06821497 Léčba recidivujícího/refrakterního SCLC, kastračně rezistentní rakoviny prostaty a folikulárního lymfomu
FÁZE I ESKALACE DÁVKY A ROZŠÍŘENÁ KOHORTOVÁ STUDIE PF-06821497 V LÉČBĚ DOSPĚLÝCH PACIENTŮ S RELAPOVANÝM/REFRAKTORNÍM MALOBĚŽNÝM RAKOVINOM PLÍCÍ (SCLC), KASTRACE REZISTENTNÍM RAKINEM PROSTATY (CRPC) A FOLLICMAULEM
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.
Part 3, which is open for enrollment is seeking men who:
- have Castration Resistant Prostate Cancer (CRPC) and
- have previously received treatment for CRPC and have progressed from the last treatment
All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort).
In the assessment phase:
- participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.
- participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule.
- participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule.
After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding.
The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
This is an open label, multi center, Phase 1 dose escalation and dose expansion study of mevrometostat (PF-06821497) administered orally BID as a single agent or in combination with SOC to patients with CRPC, SCLC, and FL. The study consists of three parts (Part 1, Part 2, and Part 3) along with the Japan and China monotherapy cohorts. Part 1 and Part 2 are closed for enrollment. Part 1 tested monotherapy in 3 cohorts (Parts 1A, 1B, and 1C); Part 2 tested combination therapy in Parts 2A (dose escalation), 2B and 2C (does expansion).
Part 3 consists of the Bioequivalence (BE) and drug-drug interaction (DDI) substudies and are open for enrollment. The BE substudy will test between 2 mevrometostat formulation to confirm that they work in the body the same way. The DDI substudy will evaluate the effect of a strong CYP3A4 (an enzyme in your body that breaks down/ removes drugs) inhibitor on the PK of mevrometostat; a strong CYP3A4 inhibitor may slow down the breakdown/ removal of drugs in your body. The Sponsor may choose to delay or discontinue any cohorts or substudies.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 1
Kontakty a umístění
Studijní kontakt
- Jméno: Pfizer CT.gov Call Center
- Telefonní číslo: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Studijní místa
-
-
-
Haskovo, Bulharsko, 6300
- Ukončeno
- Specialized Hospital for Active Treatment of Oncology - Haskovo
-
-
-
-
Chiba
-
Kashiwa, Chiba, Japonsko, 277-8577
- Aktivní, ne nábor
- National Cancer Center Hospital East
-
-
-
-
Kyǒnggi-do
-
Seongnam, Kyǒnggi-do, Jižní Korea, 13620
- Nábor
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [seoul]
-
Seoul, Seoul-teukbyeolsi [seoul], Jižní Korea, 03080
- Aktivní, ne nábor
- Seoul National University Hospital
-
Seoul, Seoul-teukbyeolsi [seoul], Jižní Korea, 07985
- Aktivní, ne nábor
- Ewha Womans University Mokdong Hospital
-
Seoul, Seoul-teukbyeolsi [seoul], Jižní Korea, 03722
- Aktivní, ne nábor
- Severance Hospital, Yonsei University Health System
-
-
Taejǒn-kwangyǒkshi
-
Daejeon, Taejǒn-kwangyǒkshi, Jižní Korea, 35015
- Aktivní, ne nábor
- Chungnam national university hospital
-
-
-
-
-
Bydgoszcz, Polsko, 85-048
- Zatím nenabíráme
- In-Vivo Sp. z o.o. In-vivo Bydgoszcz
-
Koszalin, Polsko, 75-581
- Aktivní, ne nábor
- Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie
-
Krakow, Polsko, 30-348
- Nábor
- Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
-
Rzeszów, Polsko, 35-326
- Aktivní, ne nábor
- Centrum Medyczne MEDYK
-
Warsaw, Polsko, 02-781
- Aktivní, ne nábor
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
-
-
-
-
-
Moscow, Rusko, 117186
- Aktivní, ne nábor
- LLC "Neyro-klinika"
-
Moscow, Rusko, 125284
- Ukončeno
- Moscow GBUZ "City clinical hospital n. a. S.P. Botkina" of Moscow health department
-
Moscow, Rusko, 129301
- Ukončeno
- SBHI of Moscow City Clinical Hospital
-
Omsk, Rusko, 644013
- Ukončeno
- Budgetary Healthcare Institution of Omsk region "Clinical Oncological Dispensary"
-
Saint Petersburg, Rusko, 197341
- Ukončeno
- Federal State Budgetary Institution National Medical Research Center n.a. V.A. Almazov
-
Saint Petersburg, Rusko, 197758
- Ukončeno
- Federal State Budgetary Institution National Medical Research Center for Oncology n.a. N.N.
-
Saint Petersburg, Rusko, 198255
- Ukončeno
- Saint Petersburg State Budgetary Healthcare Institution "City Clinical Oncological Dispensary"
-
Yaroslavl, Rusko, 150054
- Ukončeno
- State Budgetary Healthcare Institution of the Yaroslavl Region
-
-
Sankt-Peterburg
-
Pushkin, Sankt-Peterburg, Rusko, 196603
- Aktivní, ne nábor
- Private Medical Institution "Euromedservice"
-
-
-
-
Arizona
-
Tucson, Arizona, Spojené státy, 85719
- Aktivní, ne nábor
- Banner-University Medical Center Tucson
-
Tucson, Arizona, Spojené státy, 85719
- Aktivní, ne nábor
- The University of Arizona Cancer Center-North Campus
-
Tucson, Arizona, Spojené státy, 85724
- Aktivní, ne nábor
- The University of Arizona Cancer Center
-
Tucson, Arizona, Spojené státy, 85741
- Ukončeno
- Arizona Urology Specialists, PLLC
-
-
California
-
Anaheim, California, Spojené státy, 92801
- Aktivní, ne nábor
- Pacific Cancer Medical Center INC
-
Duarte, California, Spojené státy, 91010
- Aktivní, ne nábor
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
-
Duarte, California, Spojené státy, 91010
- Aktivní, ne nábor
- City of Hope Investigational Drug Services (IDS)
-
-
Connecticut
-
Norwalk, Connecticut, Spojené státy, 06856
- Aktivní, ne nábor
- Norwalk Hospital
-
-
Kansas
-
Fairway, Kansas, Spojené státy, 66205
- Aktivní, ne nábor
- The University of Kansas Cancer Center, Investigational Drug Services
-
Fairway, Kansas, Spojené státy, 66205
- Aktivní, ne nábor
- The University of Kansas Clinical Research Center
-
Kansas City, Kansas, Spojené státy, 66160
- Aktivní, ne nábor
- The University of Kansas Hospital
-
Kansas City, Kansas, Spojené státy, 66160
- Aktivní, ne nábor
- The University of Kansas Medical Center Medical Office Building
-
Overland Park, Kansas, Spojené státy, 66211
- Aktivní, ne nábor
- The University of Kansas Cancer Center - Indian Creek Campus
-
Westwood, Kansas, Spojené státy, 66205
- Aktivní, ne nábor
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Spojené státy, 40202
- Aktivní, ne nábor
- Norton Cancer Institute, Norton Healthcare Pavilion
-
Louisville, Kentucky, Spojené státy, 40202
- Aktivní, ne nábor
- Norton Hospital
-
Louisville, Kentucky, Spojené státy, 40202
- Aktivní, ne nábor
- Norton Cancer Institute - Downtown
-
-
Maryland
-
Rockville, Maryland, Spojené státy, 20850
- Ukončeno
- Maryland Oncology Hematology, P.A.
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02215
- Aktivní, ne nábor
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Spojené státy, 02115
- Aktivní, ne nábor
- Brigham and Women's Hospital
-
Newton, Massachusetts, Spojené státy, 02459
- Aktivní, ne nábor
- Dana Farber Cancer Institute- Chestnut Hill
-
-
Nebraska
-
Omaha, Nebraska, Spojené státy, 68130
- Nábor
- Oncology Hematology West, PC dba Nebraska Cancer Specialists
-
-
New Jersey
-
Hackensack, New Jersey, Spojené státy, 07601
- Aktivní, ne nábor
- Hackensack University Medical Center
-
Hackensack, New Jersey, Spojené státy, 07601
- Aktivní, ne nábor
- John Theurer Cancer Center at Hackensack University Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73104
- Nábor
- OU Health University of Oklahoma Medical Center
-
Oklahoma City, Oklahoma, Spojené státy, 73104
- Nábor
- Stephenson Cancer Center (chemo location)
-
-
South Carolina
-
Myrtle Beach, South Carolina, Spojené státy, 29572
- Nábor
- Carolina Urologic Research Center
-
Myrtle Beach, South Carolina, Spojené státy, 29572
- Nábor
- Parkway Surgery Center
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37203
- Nábor
- Sarah Cannon Research Institute - Pharmacy
-
Nashville, Tennessee, Spojené státy, 37203
- Nábor
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Spojené státy, 78705
- Ukončeno
- Texas Oncology - Austin Midtown
-
Dallas, Texas, Spojené státy, 75390
- Aktivní, ne nábor
- UT Southwestern Medical Center
-
Dallas, Texas, Spojené státy, 75390
- Aktivní, ne nábor
- University of Texas Southwestern Medical Center - Simmons Cancer Center
-
Dallas, Texas, Spojené státy, 75390
- Aktivní, ne nábor
- UT Southwestern University Hospital - William P. Clements, Jr
-
Dallas, Texas, Spojené státy, 75390
- Aktivní, ne nábor
- UT Southwestern University Hospital - Zale Lipshy
-
Irving, Texas, Spojené státy, 75063
- Ukončeno
- US Oncology Investigational Product Center (IPC)
-
Irving, Texas, Spojené státy, 75063
- Ukončeno
- US Oncology Investigational Products Center
-
Irving, Texas, Spojené státy, 75039
- Nábor
- NEXT Dallas
-
San Antonio, Texas, Spojené státy, 78229
- Nábor
- NEXT Oncology
-
-
Virginia
-
Fairfax, Virginia, Spojené státy, 22031
- Aktivní, ne nábor
- Virginia Cancer Specialists, PC
-
-
Washington
-
Port Angeles, Washington, Spojené státy, 98362
- Aktivní, ne nábor
- Olympic Medical Center
-
Poulsbo, Washington, Spojené státy, 98370
- Aktivní, ne nábor
- Fred Hutchinson Cancer Center Alliance Peninsula
-
Seattle, Washington, Spojené státy, 98195
- Aktivní, ne nábor
- University of Washington Medical Center
-
Seattle, Washington, Spojené státy, 98109
- Aktivní, ne nábor
- Fred Hutchinson Cancer Center
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, Čína, 510120
- Aktivní, ne nábor
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Hunan
-
Changsha, Hunan, Čína, 410013
- Aktivní, ne nábor
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Čína, 210009
- Aktivní, ne nábor
- Zhongda Hospital Southeast University
-
Nanjing, Jiangsu, Čína, 210008
- Aktivní, ne nábor
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
-
-
Sichuan
-
Chengdu, Sichuan, Čína, 610041
- Nábor
- West China Hospital, Sichuan University
-
-
Zhejiang
-
Wenzhou, Zhejiang, Čína, 325000
- Aktivní, ne nábor
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
-
Barcelona, Španělsko, 08035
- Nábor
- Hospital Universitari Vall d'Hebron
-
Barcelona, Španělsko, 08036
- Nábor
- Hospital Clinic de Barcelona
-
Barcelona, Španělsko, 08023
- Nábor
- Hospital Quironsalud Barcelona
-
Madrid, Španělsko, 28034
- Nábor
- Hospital Universitario Ramon y Cajal
-
Madrid, Španělsko, 28050
- Nábor
- Hospital Universitario HM Sanchinarro
-
Madrid, Španělsko, 28040
- Nábor
- H.U. Fundación Jiménez Díaz
-
Madrid, Španělsko, 28041
- Nábor
- Hospital Universitario 12 De Octubre
-
Málaga, Španělsko, 29010
- Nábor
- Hospital Universitario Virgen de la Victoria
-
Valencia, Španělsko, 46026
- Aktivní, ne nábor
- Hospital Universitari i Politecnic La Fe
-
-
Barecelona
-
L'Hospitalet de Llobregat, Barecelona, Španělsko, 08908
- Aktivní, ne nábor
- Institut Català d´Oncología (ICO)-H. Durán i Reynals
-
-
Castellon
-
Castellon, Castellon, Španělsko, 12002
- Aktivní, ne nábor
- Consorcio Hospitalario Provincial de Castellon
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Španělsko, 28223
- Nábor
- Hospital Quironsalud Madrid
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Španělsko, 28040
- Nábor
- Hospital Clinico San Carlos
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Part 1 and Part 2 (Closed for enrollment).
Part 3 Key Inclusion Criteria:
- Histological or cytological diagnosis of castration resistant prostate cancer.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.
- Adequate bone marrow, renal, and liver function
Part 3 Key Exclusion Criteria:
- Prior irradiation to >25% of the bone marrow.
- QTcF interval >480 msec at screening.
- Hypertension that cannot be controlled by medications (>150/90 mmHg despite optimal medical therapy).
- Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)
- Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
- Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4/5 inducers or inhibitors
- Prior enzalutamide within the last 4 weeks
- DDI SUBSTUDY:
- history of CHF or evidence of ventricular dysfunction
- fructose intolerance
- coadministration of CYP3A4 substrates
- Any history of prior malignancies, except for carcinoma in situ or non-melanoma skin cancer, prior non-hematologic malignancies >= 3 years before randomization with no subsequent recurrence or progression, Stage 0 or 1 non-hematologic cancer < 3 years before randomization that has a remote probability of recurrence or progression.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Sekvenční přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Dose Escalation (Part 1A)
Participants with SCLC, CRPC and FL will receive mevrometostat at escalating dose levels |
Oral continuous
Ostatní jména:
|
|
Experimentální: Dose Escalation (Part 1B)
Participants with FL will receive mevrometostat at escalating dose levels |
Oral continuous
Ostatní jména:
|
|
Experimentální: Dose Escalation (Part 1C)
Participants with mCRPC will receive mevrometostat at escalating dose levels. |
Oral continuous
Ostatní jména:
|
|
Experimentální: Dose Escalation (Part 2A)
Participants with mCRPC and SCLC will receive mevrometostat at escalating dose levels in combination with SOC. |
Oral continuous
Ostatní jména:
Oral continuous
Ostatní jména:
|
|
Experimentální: Dose Expansion (Part 2B)
Participants with CRPC will receive mevrometostat in combination with SOC or SOC alone. |
Oral continuous
Ostatní jména:
Oral continuous
Ostatní jména:
|
|
Experimentální: Japan Cohort
Participants with CRPC will receive mevrometostat at one or two doses |
Oral continuous
Ostatní jména:
|
|
Experimentální: China cohort
Participants will receive mevrometostat at one or two doses |
Oral continuous
Ostatní jména:
|
|
Experimentální: Dose Expansion (Part 2C)
Participants with mCRPC will receive mevrometostat at a different dose/dosing regimen than that of Part 2B in combination with SOC |
Oral continuous
Ostatní jména:
Oral continuous
Ostatní jména:
|
|
Experimentální: BE Substudy
In the assessment phase, each enrolled participant will receive single doses of the 2 different mevrometostat formulations in 3 periods with alternating dosing and washout between each dose. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
Ostatní jména:
Oral continuous
Ostatní jména:
|
|
Experimentální: DDI Substudy
The DDI substudy assessment phase will consist of 2 Cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (combination cohort). In the Cohort 1 assessment phase, each enrolled participant will receive a combination of mevrometostat and itraconazole based on preset schedule. In the Cohort 2 assessment phase, each enrolled participant will receive a combination of mevrometostat, enzalutamide, and itraconazole based on preset schedule. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
Ostatní jména:
Oral continuous
Ostatní jména:
Oral solution
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
Časové okno: Baseline up to 90 days
|
First cycle DLTs will be utilized to determine the MTD |
Baseline up to 90 days
|
|
Overall safety profile including adverse events
Časové okno: Baseline up to approximately 2 years
|
Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version [4.03]) |
Baseline up to approximately 2 years
|
|
Preliminary efficacy determination as evaluated by disease specific response criteria
Časové okno: Through study completion, approximately 2 years past last patient first visit.
|
Objective response using Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC). Progression-free survival in Part 2B in patients with CRPC. |
Through study completion, approximately 2 years past last patient first visit.
|
|
Overall safety profile including laboratory abnormalities
Časové okno: Baseline up to approximately 2 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version [4.03]), and timing. |
Baseline up to approximately 2 years
|
|
Overall safety profile including vital signs
Časové okno: Baseline up to approximately 2 years
|
Vital sign changes from baseline including blood pressure, heart rate, ECG changes. |
Baseline up to approximately 2 years
|
|
Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival
Časové okno: Baseline until disease progression or death or through study completion (approx 2 years)
|
PCWG3 |
Baseline until disease progression or death or through study completion (approx 2 years)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Evaluate time to event anti-tumor activity of mevrometostat including progression-free survival (PFS), PSA50, Duration of Response (DoR), Time to first skeletal related event and Time to symptomatic skeletal related event, depending on tumor type.
Časové okno: Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
Time to event endpoints based on Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC) |
Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
|
Evaluate overall survival
Časové okno: Baseline up to approximately 2 years
|
Median time to death proportion of patients alive at 6 months, 1 year, and 2 years. |
Baseline up to approximately 2 years
|
|
Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)
Časové okno: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Časové okno: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Area Under the Curve (AUC)
Časové okno: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)
Časové okno: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)
Časové okno: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)
Časové okno: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Singe dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Evaluate the impact of mevrometostat on patient reported outcomes.
Časové okno: At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
Quality of Life and Time to Functional Status Deterioration as assessed by FACT-P. |
At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
|
Impact of mevrometostat in combination with enzalutamide, enzalutamide alone and mevrometostat alone on symptoms and symptomatic toxicity
Časové okno: At specific time points from Cycle1 Day 1 to end of treatment
|
Questionnaire customized from PRO-CTCAE. |
At specific time points from Cycle1 Day 1 to end of treatment
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Pfizer CT.gov Call Center, Pfizer
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Patologické procesy
- Novotvary podle místa
- Novotvary
- Atributy nemoci
- Onemocnění imunitního systému
- Nemoci dýchacích cest
- Novotvary podle histologického typu
- Plicní onemocnění
- Novotvary dýchacího traktu
- Novotvary hrudníku
- Novotvary plic
- Lymfatická onemocnění
- Lymfoproliferativní poruchy
- Imunoproliferativní poruchy
- Lymfom, Non-Hodgkin
- Lymfom
- Karcinom, Bronchogenní
- Bronchiální novotvary
- Patologické stavy, příznaky a symptomy
- Hemická a lymfatická onemocnění
- Opakování
- Malobuněčný karcinom plic
- Lymfom, folikulární
- Heterocyklické sloučeniny, 1 kruh
- Heterocyklické sloučeniny
- Azoly
- Triazoles
- Piperaziny
- Itrakonazol
- Enzalutamid
- PF06821497
Další identifikační čísla studie
- C2321001
- 2023-509179-18-00 (Identifikátor registru: CTIS (EU))
- EZH2 (Jiný identifikátor: Alias Study Number)
- 2023 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .